stars 1 stars 2 stars 3

Alvarius is a neuroscientific pharmaceutical company developing therapeutics for diseases of addiction and demyelination. We use both traditional and psychedelic medicine in our scientific development programme in efforts to discover novel therapeutics to help both veterans and civilians who are struggling with these debilitating and life changing diseases. Our aim is to change how these conditions are treated for the better. We are currently seeing a focus on the use of psychedelic medicine to treat many neurological and chronic conditions as we have witnessed that psychedelics offer the opportunity to study these changes in the cells reliably at the molecular level. This could help us understand what is required from a neurobiological standpoint to achieve different states of consciousness. Our clinical research programme for addiction is focused on 5-Methoxy- Dimethyltryptamine (5-Meo- DMT), a compound is a psychedelic of the tryptamine class. It is found in a wide variety of plant species, and also is secreted by the glands of at least one toad species, the Colorado River toad. This psychedelic has been utilised for many years, having been first synthesized in 1936 and according to Forbes reporter is transforming lives. (5-MeO-DMT: The 20-Minute Psychoactive Toad Experience That’s Transforming Lives, David E. Carpenter, February 2020).

Website http://www.alvarius.com
Employees 1 (1 on RocketReach)
Founded 2019
Industry Hospitals and Health Care

Alvarius Questions

James L. is the Co-Founder of Alvarius.

1 people are employed at Alvarius.

Top Alvarius Employees

G2 Leader Summer 2026 G2 Best Est ROI Mid-Market Summer 2026 G2 Easiest Admin Mid-Market Summer 2026 G2 Most Implementable Summer 2026 G2 Best Results Mid-Market Summer 2026 G2 Lead Capture Mid-Market Summer 2026 Inc Fastest Growing Private Companies 2026 Inc Best Workplace 2026
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users